maurice colson

Silo Wellness Mourns the Passing of Board Member, Maurice J. Colson

Silo Wellness Inc. (CSE: SILO), a wellness company in the psychedelics and functional mushroom marketplaces, regrets to announce the passing of board member, Maurice ‘Moe' Colson, who passed away on March 26, 2021.

"It is with great sadness that I announce the recent passing of our Board colleague, Moe Colson," stated Douglas K. Gordon, Chief Executive Officer of Silo Wellness. "Moe is remembered as a good friend, devoted husband, father and grandfather as well as trusted advisor."

Mr. Colson served as board member while at Silo Wellness, since the completion of the company's successful RTO transaction with Yukoterre Resources Inc., in early March of this year. An investment banker, Mr. Colson served as company director for Yukoterre since May 2019. After more than three decades of experience in domestic and international capital markets, Moe was instrumental in helping to transform Silo Wellness into a publicly-traded company on the Canadian Securities Exchange (CSE).

"I was saddened to learn that our friend and colleague Moe Colson had passed away," added Ryan Ptolemy, Chief Financial Officer with Silo Wellness. "For many years, I worked with Moe, who was such a great person and a friend."

About Silo Wellness
The mission of Silo Wellness is to improve health and wellness by developing and introducing psychedelic medicine to reduce trauma and increase performance by destigmatizing the active compounds in psychedelics and innovating ease of administration and ingestion. Silo Wellness intends to introduce new, safe and affordable alternatives to current medicines by facilitating entry into new and emerging markets where psychedelics are legal by conducting ketamine and psilocybin wellness retreats and elsewhere by manufacturing and distributing functional mushrooms.

Since its inception, Silo Wellness' activities have focused on: (1) development of psilocybin-free functional mushroom tinctures; (2) the development of the formulation of a psilocybin nasal spray in Jamaica; and (3) offering of Jamaican and Oregon psychedelic wellness retreats as well as the cultivation of psychedelic mushrooms in Jamaica. None of Silo Wellness' products claim to cure or mitigate any physical or mental disease, symptoms, disorders or abnormalities.

For further information, please contact: www.SiloWellness.com

Media Relations:
Stuart Kirby, VP of Marketing & Communications
press@silowellness.com

Silo Wellness Investor Relations:
(604) 343-2724
IR@empiregroupir.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. Other than statements of historical fact, all statements are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to the business plans of Silo Wellness. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties and the potential impact of COVID-19. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Silo Wellness assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

Born Defense

Born Defense Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Born Defense

Born Defense

Psychedelic Healing Right Now & Pharmaceutical Biotech

Psychedelic Healing Right Now & Pharmaceutical Biotech Keep Reading...
Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies

Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies

Company's clinical research operations and therapist training programs directly positioned to support accelerated research and commercialization timelinesNuminus Wellness Inc. (OTC: NUMIF) today acknowledged the Executive Order signed by President Donald J. Trump directing United States federal... Keep Reading...
Emyria Limited

Emyria Launches Global Services Platform Targeting International Drug Sponsors

Emyria’s established, world-first, unique national clinical delivery network to drive a new services-led revenue stream focused on global drug sponsors.

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”), a leader in innovative mental health treatments, is pleased to announce the launch of its Empax Global Partnership Program, a new services platform enabling international drug sponsors to access Emyria’s established clinical delivery... Keep Reading...
Numinus Wellness Provides Update Regarding Listing Status

Numinus Wellness Provides Update Regarding Listing Status

Numinus Wellness Inc. (TSX: NUMI) (OTC Pink: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with an emphasis on safe, evidence-based psychedelic-assisted therapies, is providing an update regarding its listing status on the... Keep Reading...
Numinus Wellness Provides Corporate Update

Numinus Wellness Provides Corporate Update

Numinus Wellness Inc. (TSX: NUMI) (OTC: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is providing a corporate update.Corporate UpdateOver the past year,... Keep Reading...
Numinus Wellness Advises of a Change of Auditor

Numinus Wellness Advises of a Change of Auditor

Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is advising of a change of its auditor. The Company's previous... Keep Reading...
Lobe Sciences Reports First Quarter 2026 Results and Highlights

Lobe Sciences Reports First Quarter 2026 Results and Highlights

VANCOUVER, BC / ACCESS Newswire / February 3, 2026 / lobe sciences ltd. (CSE:LOBE,OTC:LOBEF)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases with unmet medical needs, today reported unaudited financial results for the first... Keep Reading...
Born Defense

Born Defense Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Interactive Chart

Latest Press Releases

Related News